169 related articles for article (PubMed ID: 30353601)
41. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
42. Olaratumab: First Global Approval.
Shirley M
Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
[TBL] [Abstract][Full Text] [Related]
43. Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas S; Chamberlain F; Carter T; Slater S; Cojocaru E; Lambourn B; Stansfeld A; Todd R; Verrill M; Ali N; Jones RL; Simmonds P; Keay N; McCarty H; Strauss S; Karavasilis V; Dileo P; Benson C
Clin Sarcoma Res; 2020; 10():9. PubMed ID: 32391141
[TBL] [Abstract][Full Text] [Related]
44. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
[TBL] [Abstract][Full Text] [Related]
45. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
46. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
Vincenzi B; Badalamenti G; Napolitano A; Spalato Ceruso M; Pantano F; Grignani G; Russo A; Santini D; Aglietta M; Tonini G
Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
[TBL] [Abstract][Full Text] [Related]
47. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
48. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Hakenberg OW; Perez-Gracia JL; Castellano D; Demkow T; Ali T; Caffo O; Heidenreich A; Schultze-Seemann W; Sautois B; Pavlik I; Qin A; Novosiadly RD; Shahir A; Ilaria R; Nippgen J
Eur J Cancer; 2019 Jan; 107():186-195. PubMed ID: 30573277
[TBL] [Abstract][Full Text] [Related]
49. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1075-1082. PubMed ID: 30929053
[TBL] [Abstract][Full Text] [Related]
50. Olaratumab for the treatment of soft-tissue sarcoma.
Pender A; Jones RL
Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
[TBL] [Abstract][Full Text] [Related]
52. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
53. Olaratumab Approved for Soft-Tissue Sarcoma.
Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
[TBL] [Abstract][Full Text] [Related]
54. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
Pender A; Jones RL
Clin Pharmacol; 2017; 9():159-164. PubMed ID: 29270033
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
56. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
57. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
[TBL] [Abstract][Full Text] [Related]
58. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Sessa C; Perotti A; Noberasco C; De Braud F; Gallerani E; Cresta S; Zucchetti M; Viganò L; Locatelli A; Jimeno J; Feilchenfeldt JW; D'Incalci M; Capri G; Ielmini N; Gianni L
Eur J Cancer; 2009 May; 45(7):1153-1161. PubMed ID: 19114300
[TBL] [Abstract][Full Text] [Related]
59. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Chawla SP; Cranmer LD; Van Tine BA; Reed DR; Okuno SH; Butrynski JE; Adkins DR; Hendifar AE; Kroll S; Ganjoo KN
J Clin Oncol; 2014 Oct; 32(29):3299-306. PubMed ID: 25185097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
